Freeline Therapeutics’ $120 Million Series C Investment

Latham & Watkins advised Novo Holdings A/S (Novo) as the lead investor in the investment.

Freeline Therapeutics raised US$120 million in its Series C investment, co-led by Novo, Eventide Asset Management and Wellington Management Company, with additional participation from Cowen Healthcare Investments, Acorn Bioventures and Ample Plus Fund.

Freeline Therapeutics is a biotechnology company focused on developing curative gene therapies for chronic systemic diseases.

Established in 1999, Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation. The purpose of the investments of Novo Holdings is both to grow the assets of the Foundation and to deliver a return that the Foundation can distribute for scientific, social and humanitarian purposes to improve the lives of people and the sustainability of society.

Latham’s team advising Novo was led by London corporate partner Robbie McLaren (Picture), with associates Emily Cridland and Georgina Scott.

Involved fees earner: Emily Cridland – Latham & Watkins; Robbie McLaren – Latham & Watkins; Georgina Scott – Latham & Watkins;

Law Firms: Latham & Watkins;

Clients: Novo Holdings A/S;